License

License Not Specified

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

An open-label trial with TMC278 25 mg qd in combination with a background regimen containing 2 nucleosidenucleotide reverse transcriptase inhibitors in HIV-1 infected subjects who participated in TMC278 clinical trials

The primary objective of the trial is to provide continued access to TMC278 for subjects who were randomized and treated with TMC278 in the Phase IIb C204 or Phase III trials C209 and C215 and who at the time of roll-over experience and are expected to continue experiencing clinical benefit from TMC278 treatment

FieldValue
Modified
2019-12-23
Release Date
2019-05-09
Identifier
0505a119-67dc-44c9-aa01-1963ac6c6f8a
License
License Not Specified
Public Access Level
Public